Prognosis in MDS is dependent on the particular MDS subtype. Whereas RAEB2 patients have a median overall survival of 9 months, 5q- MDS patients have a median overall survival of nearly 12 years. Dear
Continue readingPrehabilitation is an evidence-based process that occurs in the time between diagnosis and the start of acute care. The goal is to prepare a patient with multiple myeloma as much as possible…” Hi
Continue reading“However, after the sound goes into noise, all the benefits to our senses stop, and the risk of potential health complications increases.” To learn more about the Sound Proof Pros- Noise can
Continue reading“These results showed that Cannabidiol by itself or in synergy with BORT (velcade) strongly inhibited growth, arrested cell cycle progression and induced Multiple Myeloma cell death Hi Dave, I am
Continue readingI also find a positive relationship between charitable giving and self-reported health status. As the amount of the donation increases, health status improves…” Surviving multiple myeloma
Continue readingMultiple myeloma (MM) genetic expression changes with chemotherapy. Can lifestyle therapies change MM genetics as well? A multiple myeloma diagnosis is serious. However, there is no genetic pre-disposition
Continue reading“In (newly diagnosed multiple myeloma) patients, fatigue was one of the major symptoms in 32 percent of patients and related to anemia and the other symptoms due to MM…” One of the most common
Continue reading“…new treatment formulation delivered through a skin patch, maintaining an optimal blood level of the medicine (revlimid) for prolonged periods of time.” Low-dose multiple myeloma maintenance
Continue reading“…achieving CR after HDT/SCT (ASCT) is the most important prognostic factor in Multiple Myeloma, even after long-term follow-up…” David, I have had full blown multiple myeloma
Continue readingExercise may have yet another benefit – the right amount at the right time could make multiple myeloma (MM) treatments such as radiation and chemotherapy more effective…” The many studies
Continue reading“daratumumab was approved for use in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation” There’s
Continue readingEssiac demonstrated antioxidant (12) and cytotoxic properties in vitro (6) (11), but stimulated growth of human breast cancer cells both via estrogen receptor (ER)-dependent and ER-independent pathways (3). Dear
Continue reading